Literature DB >> 7503673

Inhibition of the intracellular transport of influenza viral RNA by actinomycin D.

U Vogel1, C Scholtissek.   

Abstract

In primary chicken embryo cells infected with fowl plague virus addition of actinomycin D at defined times during the infection cycle has different consequences on viral replication. If actinomycin D is added immediately after infection with a concentration, which inhibits viral RNA synthesis only partially, it interferes with the nucleo-cytoplasmic transport of all viral RNA species (mRNA and vRNA) so far tested. If actinomycin D is present during infection (adsorption, penetration and uncoating) no viral RNA is synthesized, and the nucleocapsid of the infecting virus does not reach the nucleus, as shown by fluorescent antibodies. Therefore the primary effect of actinomycin D on influenza virus replication is on the transport of the incoming vRNPs from the cytoplasm to the cell nucleus, which is the cell compartment where transcription takes place.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7503673     DOI: 10.1007/bf01384336

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  13 in total

1.  THE EFFECTS OF ACTINOMYCIN D AND ULTRAVIOLET IRRADIATION ON THE PRODUCTION OF FOWL PLAGUE VIRUS.

Authors:  R D BARRY
Journal:  Virology       Date:  1964-12       Impact factor: 3.616

2.  Transcription-dependent and transcription-independent nuclear transport of hnRNP proteins.

Authors:  S Piñol-Roma; G Dreyfuss
Journal:  Science       Date:  1991-07-19       Impact factor: 47.728

3.  Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import.

Authors:  K Martin; A Helenius
Journal:  Cell       Date:  1991-10-04       Impact factor: 41.582

4.  The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses.

Authors:  F X Bosch; M Orlich; H D Klenk; R Rott
Journal:  Virology       Date:  1979-05       Impact factor: 3.616

Review 5.  Priming of influenza viral RNA transcription by capped heterologous RNAs.

Authors:  R M Krug
Journal:  Curr Top Microbiol Immunol       Date:  1981       Impact factor: 4.291

6.  Transcription and replication of influenza virus RNA.

Authors:  T Barrett; A J Wolstenholme; B W Mahy
Journal:  Virology       Date:  1979-10-15       Impact factor: 3.616

7.  Specific inhibition of the synthesis of influenza virus late proteins and stimulation of early, M2, and NS2 protein synthesis by 3-deazaadenosine.

Authors:  A A Fischer; K Müller; C Scholtissek
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

8.  Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm.

Authors:  S Piñol-Roma; G Dreyfuss
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

9.  Influenza A virus late mRNAs are specifically retained in the nucleus in the presence of a methyltransferase or a protein kinase inhibitor.

Authors:  U Vogel; M Kunerl; C Scholtissek
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

10.  Influenza virus gene expression: control mechanisms at early and late times of infection and nuclear-cytoplasmic transport of virus-specific RNAs.

Authors:  G I Shapiro; T Gurney; R M Krug
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

View more
  6 in total

1.  Selective inhibition of splicing at the avian sarcoma virus src 3' splice site by direct-repeat posttranscriptional cis elements.

Authors:  W Guo; S C Winistorfer; C M Stoltzfus
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  The 5' ends of Thogoto virus (Orthomyxoviridae) mRNAs are homogeneous in both length and sequence.

Authors:  C Albo; J Martín; A Portela
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

3.  Thogoto and Dhori virus replication is blocked by inhibitors of cellular polymerase II activity but does not cause shutoff of host cell protein synthesis.

Authors:  J Siebler; O Haller; G Kochs
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

Review 4.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

Review 5.  Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Authors:  Xiaoai Wu; Xiuli Wu; Qizheng Sun; Chunhui Zhang; Shengyong Yang; Lin Li; Zhiyun Jia
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

6.  Cathepsin B plays a key role in optimal production of the influenza A virus.

Authors:  Macon D Coleman; Soon-Duck Ha; S M Mansour Haeryfar; Stephen Dominic Barr; Sung Ouk Kim
Journal:  J Virol Antivir Res       Date:  2018-05-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.